Quantum-Si Inc has announced a significant milestone in its Proteus development program, successfully demonstrating the detection of 19 amino acids. This achievement is crucial as the company aims to detect all 20 amino acids by the end of 2026. The progress underscores Quantum-Si's commitment to advancing its technology in the competitive field of proteomics.
Founded in Branford, Connecticut, Quantum-Si operates under the Standard Industrial Classification of Measuring & Controlling Devices, NEC (SIC 3829). The company trades on the Nasdaq under the ticker symbol QSI. Quantum-Si focuses on transforming protein analysis through single-molecule protein sequencing, making it a key player in the biotechnology sector.
In its recent SEC filing dated October 8, 2026, Quantum-Si detailed its progress in the Proteus program, stating, "the Company has demonstrated detection of 19 amino acids in its Proteus development program." This marks a significant step toward their goal of achieving detection of all 20 amino acids, which they expect to demonstrate by year-end 2026.
This advancement may have a profound impact on researchers and laboratories that rely on precise protein analysis. The ability to detect a broader range of amino acids could enhance the capabilities of Quantum-Si's instruments, thereby attracting more customers and potentially increasing market share.
Looking ahead, Quantum-Si is focused on deploying the 19-amino-acid detection capability into a developmental sequencing kit for routine use on its Proteus instruments. The filing does not specify further actions or timelines beyond this development.